SABR-Dual: A phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer

Abstract

Abstract Background: Dose-escalated radiotherapy is known to improve progression free survival in patients with localized prostate cancer, and recent advances have led to the standardization of ultrahypofractionated stereotactic ablative radiotherapy (SABR) delivered in just 5-fractions. Based on the known effectiveness of the accepted though invasive 2-fraction treatment method of high-dose-rate brachytherapy and given the ubiquity of prostate cancer, a further reduction in the number of treatments of external-beam SABR is possible. This study aims to evaluate the safety, efficacy, and non-inferiority of generalizable 2-fraction SABR compared to the current 5-fraction regimen. Methods: 608 patients will be enrolled on this phase II/III randomized control trial. Eligible patients will have previously untreated low- or favorable intermediate-risk adenocarcinoma of the prostate. Patients will be randomized between standard SABR of 40 Gy in 5 fractions given every-other-day and 27 Gy in 2 fractions at least two days apart but completing within seven days. MRI-based planning, SpaceOAR VueTM insertion, and fiducial marker placement are required, and SABR will be delivered on a standard CT-guided linear accelerator. The primary endpoint will be freedom from disease progression, with additional secondary clinical, toxicity, and quality of life endpoints. Discussion: This study will be the largest prospective randomized trial, adequately powered to demonstrate non-inferiority, comparing 2-fraction SABR to standard 5-fraction SABR for localized prostate cancer. As the protocol does not necessitate use of an MRI-LINAC or other adaptive technologies, results will be broadly generalizable to the wider community. Trial registration: This trial was prospectively registered on Health.gov.il Health.gov.il identifier: MOH_2022-08-30_012007